Cediranib
Recurrent Lung Carcinoma
National Cancer Institute (NCI)Small moleculePhase 1Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Romidepsin National Cancer Institute (NCI) | Phase 1 | CC |
Rapamycin Emory University | Phase 1 | CC |
RASDEGAFUSP ALFA Roswell Park Cancer Institute | Phase 1 | CC |
mk-3475 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →